Sputnik V
Posted on June 2nd, 2021
Sputnik V Vaccine
GENERAL INFORMATION
Sputnik V is the world’s first registered vaccine based on a well-studied human adenoviral vector-based platform. Sputnik V is already registered in more than 65 countries.
The ongoing Sputnik V post-registration clinical trial in Russia involved more than 31,000 volunteers. Phase 3 clinical trials of Sputnik V have been conducting in the UAE, India, Venezuela and Belarus.
Sputnik V is one of the three vaccines in the world with efficacy of over 90%. The Vaccine’s efficacy is confirmed at 91.6% based on the analysis of data on 19,866 volunteers, who received both the first and second doses of the Sputnik V vaccine or placebo at the final control point of 78 confirmed COVID-19 cases.
According to analysis of data from 3.8 million vaccinated persons in Russia Sputnik V demonstrates 97.6% efficacy.
RDIF jointly with partners and manufacturers is ramping up the production of Sputnik V. The cost of one dose of the vaccine for international markets is less than $10 (Sputnik V is a two dose vaccine). The vaccine can be stored at a temperature of +2 to +8 degrees Celsius, which allows for easy distribution worldwide, including hard-to-reach regions.
The vaccine supplies for the global market will be produced by RDIF’s international partners in India, Brazil, China, South Korea and other countries.
This website has been created to provide accurate and up-to-date information about Sputnik V.
Russian Health Ministry registration certificate
The vaccine is named after the first Soviet space satellite. The launch of Sputnik-1 in 1957 reinvigorated space research around the world, creating a so called Sputnik moment” for the global community.
The Russian Ministry of Health, the Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announce that Sputnik Light, a single dose COVID-19 vaccine, has received authorization for use in Russia.
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V – the world’s first registered vaccine against coronavirus.
The single dose Sputnik Light vaccine demonstrated 79.4% efficacy according to analyzed data taken from 28 days after the injection was administered as part of Russia’s mass vaccination program between 5 December 2020 and 15 April 2021.
An efficacy level of almost 80% is higher than that of many two-dose vaccines.
Sputnik Light has proven effective against all new strains of coronavirus, as demonstrated by the Gamaleya Center during laboratory tests.
Phase I/II of the Safety and Immunogenicity Study of the Sputnik Light vaccine has demonstrated that:
- Sputnik Light can elicit the development of antigen specific IgG antibodies in 96.9% of individuals on the 28th day after vaccination;
- The Sputnik Light vaccine elicits the development of virus neutralizing antibodies in 91.67% of individuals on the 28th day post immunization;
- Cellular immune response against the S Protein of SARS-CoV-2 develops in 100% of volunteers on the 10th day;
- The immunization of individuals with pre-existing immunity against SARS-CoV-2 with Sputnik Light can elicit the increase of the level of antigen specific IgG antibodies by more than 40x in 100% of subjects 10 days after immunization;
- No serious adverse events were registered after vaccination with Sputnik Light.
The two dose Sputnik V vaccine remains the main vaccination tool.